Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04086160
Other study ID # HSEARS20190518001
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date August 22, 2019
Est. completion date December 31, 2023

Study information

Verified date February 2023
Source The Hong Kong Polytechnic University
Contact Shu-Mei Wang, PhD
Phone 852-27664197
Email shumei.wang@polyu.edu.hk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purposes of this research are to investigate (1) if schizophrenia patients and at-risk individuals present bradykinesia and dyskinesia and (2) if tDCS improves motor performance in schizophrenia patients and at-risk individuals. The first hypothesis is that both schizophrenia patients and at-risk individuals show bradykinesia and dyskinesia, and the motor symptoms are more severe in the former than the latter. The second hypothesis is that tDCS improves motor performance in schizophrenia patients and at-risk cases.


Recruitment information / eligibility

Status Recruiting
Enrollment 120
Est. completion date December 31, 2023
Est. primary completion date December 31, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 12 Years to 65 Years
Eligibility Inclusion Criteria for schizophrenia patients: - a diagnosis of schizophrenia without other psychiatric diseases - having stable psychotic symptoms - a score of 22 or above in Hong Kong version Montreal Cognitive Assessment - having no neurological diseases and no medical conditions that affect motor performance No Exclusion Criteria. Inclusion Criteria for at-risk individuals: - a score of nine or above in the Chinese version of the 16-item Prodromal Questionnaire (CPQ-16) - a score of 22 or above in Hong Kong version Montreal Cognitive Assessment - having no diagnosis of psychiatric diseases - having no neurological diseases and no medical conditions that affect motor performance No Exclusion Criteria. Inclusion Criteria for healthy controls: - a score less than nine in CPQ-16 - a score of 22 or above in Hong Kong version Montreal Cognitive Assessment - having no diagnosis of psychiatric diseases - having no neurological diseases and no medical conditions that affect motor performance. No Exclusion Criteria.

Study Design


Intervention

Device:
Transcranial direct current stimulation device (Soterix Medical, New York, NY)
Transcranial direct current stimulation (tDCS) is a non-invasive intervention, which applies low-amplitude direct electric currents to the brain through scalp electrodes. The real (2mA) or sham tDCS intervention will be given for a total of eight sessions in four weeks with 20 minutes per session.

Locations

Country Name City State
Hong Kong Hong Kong Polytechnic University Kowloon

Sponsors (1)

Lead Sponsor Collaborator
Dr WANG Shumei

Country where clinical trial is conducted

Hong Kong, 

Outcome

Type Measure Description Time frame Safety issue
Primary Motion analysis by using an eight-camera motion capture system (VICON; Oxford Metrics Group, Oxford, UK) normalized movement time (representing severity of parkinsonism). Unit: second/mm Within one week right before the 1st session of tDCS
Primary Motion analysis by using an eight-camera motion capture system (VICON; Oxford Metrics Group, Oxford, UK) normalized movement time (representing severity of parkinsonism). Unit: second/mm Within one week right after the 8th (last) session of tDCS
Primary Motion analysis by using an eight-camera motion capture system (VICON; Oxford Metrics Group, Oxford, UK) normalized number of movement units (representing severity of dyskinesia). Unit: units/mm Within one week right before the 1st session of tDCS
Primary Motion analysis by using an eight-camera motion capture system (VICON; Oxford Metrics Group, Oxford, UK) normalized number of movement units (representing severity of dyskinesia). Unit: units/mm Within one week right after the 8th (last) session of tDCS
See also
  Status Clinical Trial Phase
Recruiting NCT05039489 - A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia N/A
Completed NCT05111548 - Brain Stimulation and Cognitive Training - Efficacy N/A
Completed NCT05321602 - Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder Phase 1
Completed NCT04503954 - Efficacy of Chronic Disease Self-management Program in People With Schizophrenia N/A
Completed NCT02831231 - Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium Phase 1
Completed NCT05517460 - The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center N/A
Completed NCT03652974 - Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy Phase 4
Recruiting NCT04012684 - rTMS on Mismatch Negativity of Schizophrenia N/A
Recruiting NCT04481217 - Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia N/A
Completed NCT00212784 - Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935) Phase 3
Completed NCT04092686 - A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia Phase 3
Completed NCT01914393 - Pediatric Open-Label Extension Study Phase 3
Recruiting NCT03790345 - Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics Phase 2/Phase 3
Recruiting NCT05956327 - Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training N/A
Terminated NCT03261817 - A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders N/A
Terminated NCT03209778 - Involuntary Memories Investigation in Schizophrenia N/A
Completed NCT02905604 - Magnetic Stimulation of the Brain in Schizophrenia or Depression N/A
Recruiting NCT05542212 - Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia N/A
Completed NCT04411979 - Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia N/A
Terminated NCT03220438 - TMS Enhancement of Visual Plasticity in Schizophrenia N/A